Related Experiment Videos
[Pharmacokinetic and clinical studies of cefdinir in pediatric field]
N Fukushima1, Y Wagatsuma, A Takase
1Department of Pediatrics, Sapporo City General Hospital.
Insights
Cefdinir (CFDN) demonstrated an 88.5% efficacy rate in treating pediatric bacterial infections. This antibiotic showed favorable pharmacokinetics and a good safety profile, with diarrhea as the only noted adverse reaction.
Area of Science:
- Pediatric infectious diseases
- Pharmacology
- Clinical microbiology
Background:
- Bacterial infections pose a significant health challenge in pediatric populations.
- Effective and safe antibiotic options are crucial for managing these infections.
Purpose of the Study:
- To evaluate the efficacy and safety of Cefdinir (CFDN) in pediatric patients.
- To assess the pharmacokinetic profile of Cefdinir in children.
Main Methods:
- Pharmacokinetic analysis in 4 male children (9-13 years) receiving oral Cefdinir (3 mg/kg or 6 mg/kg).
- Clinical evaluation of Cefdinir (5% fine granules) in 26 pediatric patients with various bacterial infections.
- Monitoring of therapeutic response and adverse reactions.
Main Results:
- Pharmacokinetics showed peak plasma levels between 0.45-1.16 microgram/ml and half-lives of 1.48-2.23 hours.
- An overall efficacy rate of 88.5% was observed across treated infections, including pneumonia, bronchitis, pharyngitis, scarlet fever, otitis media, and skin infections.
- Diarrhea was the sole adverse reaction reported in one patient.
Conclusions:
- Cefdinir is an effective and safe therapeutic option for treating bacterial infections in pediatric patients.
- The drug exhibits favorable pharmacokinetic properties in children.
- Cefdinir presents a valuable addition to the pediatric antibiotic armamentarium.
Abstract:
Cefdinir (CFDN) was evaluated for its efficacy and safety. The following results were obtained. 1. Pharmacokinetic study: CFDN was evaluated pharmacokinetically in 4 male children aged 9 to 13. CFDN was given orally to 3 children at a dose of 3 mg/kg. Peak plasma levels of 0.71 microgram/ml, 0.78 microgram/ml and 0.45 microgram/ml were attained in the 3 children, respectively, at 4 hours after dosing. Half-lives of CFDN in serum were 1.78 hours, 1.48 hours and 2.23 hours, respectively. The 12-hour urinary recovery rates of CFDN were 17.4%, 28.1% and 6.2%. When CFDN was given orally to the remaining child at a dose of 6 mg/kg, the peak plasma level was attained at 4 hours after dosing with a level of 1.16 micrograms/ml. T 1/2 was 1.78 hours. The 12-hour urinary recovery rate of CFDN was 15.0%. 2. Clinical study: CFDN 5 percent fine granules were given to 26 patients with infections; 2 with pneumonia, 4 with acute bronchitis, 1 with chronic bronchitis, 12 with pharyngitis, 4 with scarlet fever, 1 with otitis media and 2 with skin and soft tissue infections. Therapeutic responses were "excellent" in 15, "good" in 8, "fair" in 1 and "poor" in 2, with an efficacy rate of 88.5%. 3. Adverse reactions: As for adverse reactions, diarrhea was noted in 1 patient. It was concluded that CFDN is a useful drug for the treatment of the bacterial infections in pediatrics.